This was the stock's second consecutive day of losses.

Inovio plans to begin submitting the BLA for INO-3107 in mid-2025, with a goal of achieving FDA acceptance for filing by year-end 2025. Priority review will also be requested.

Citizens JMP lowered the firm’s price target on Inovio (INO) to $12 from $18 and keeps an Outperform rating on the shares. Inovio expressed ...

Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results ...

Reports Q4 revenue $117,000, consensus $25,000. “INOVIO’s (INO) recent progress puts us on the cusp of achieving several long-term goals for ...

Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...

Shares of Inovio Pharmaceuticals stock opened at $1.98 on Wednesday. The company has a market capitalization of $51.68 million, a PE ratio of -0.94 and a beta of 0.89. Inovio Pharmaceuticals has a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...